Cancer News and Research

Latest Cancer News and Research

Study compares advertising tactics between indoor tanning and tobacco industries to market unhealthy products

While the proven negative health consequences of smoking and tanning are undeniable, tobacco and indoor tanning advertisers would like consumers to think otherwise. In fact, a new study comparing the tactics used in advertising tobacco and indoor tanning products found several similarities in how these two industries market unhealthy products.

1 Mar 2010

SUVmax in head and neck squamous cell carcinoma patients predict overall survival

The maximal standardized uptake value (called SUVmax) measured from FDG PET readings taken from the primary tumor in head and neck squamous cell carcinoma patients before treatment is a strong predictor of disease-specific survival, overall survival and disease-free survival, while pretreatment SUVmax for lymphodenopathy is strongly associated with distant metastasis, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

1 Mar 2010

Determining personal risk for genetic disorders essential

Genetic diseases affect an estimated 12 million Americans, yet according to a survey of 1,000 people conducted by the Genetic Disease Foundation (GDF), while two-thirds of those surveyed were willing to and saw the benefits of undergoing genetic testing, close to 80 percent had never talked to their physician about genetic screening – an inconsistency that can have serious implications on a person's overall health and the health of their immediate family members.

1 Mar 2010

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

SIMPLE Antibody(TM) Platform Delivers Unprecedented Choice of Ultra-Potent Functional Antibody Leads Against Challenging Soluble and Cell Surface Targets. - ARGX-109, a Fully Human mAb Targeting Autoimmune, Inflammation and Oncology Indications, Enters Preclinical Development in Less Than 12 Months From Start of Discovery.

1 Mar 2010

Researchers figure out how ATP molecule broken down in cells

Researchers at the Louisiana State University Health Sciences Center have figured out how ATP is broken down in cells, providing for the first time a clear picture of the key reaction that allows cells in all living things to function and flourish.

1 Mar 2010

Study evaluates possible diet associations with ovarian cancer survival

2009 estimates projected that in the United States alone 21,550 new cases of ovarian cancer would be diagnosed and 14,600 women would die of the disease. Often diagnosed in late stages, ovarian cancer has an asymptomatic onset and a relatively low 5-year survival rate of about 45%. Consequently investigation linked to survivorship is critical.

1 Mar 2010

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

The Board of Directors of Ipsen, chaired by Jean-Luc Bélingard, met on 26 February 2010 to review the Group’s results for 2009, published today.

1 Mar 2010

New method using SGR to calculate rate of tumour growth developed

When treating cancer, it is an advantage to know the rate of growth of the cancer tumour. The standard method currently used to determine tumour growth, however, is erroneous. This is the conclusion of scientists at the University of Gothenburg, Sweden, who have developed a new model.

1 Mar 2010

Breastfeeding and better hygiene may protect against peptic ulcer bacterium infection

Young children in developing countries are infected at an early age with the bacterium Helicobacter pylori, which can cause peptic ulcers and stomach cancer. New findings show that childrens´ immune responses help in fighting the bacteria. In addition, breastfeeding and better hygiene appear to protect against infection. The results provide hope for a vaccine, according to research from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

1 Mar 2010

Aprepitant drug can reduce nausea and vomiting when combined with other anti-nausea drugs

Bone marrow transplant patients say two of the most debilitating side effects of the treatment are nausea and vomiting caused by chemotherapy and radiation.

1 Mar 2010

ADVENTRX' ANX-530 NDA: FDA issues refuse to file letter

ADVENTRX Pharmaceuticals, Inc. announced today that it received a refuse to file letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion). In the letter, the FDA indicated that the data included in the initial submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. FDA identified only the one chemistry, manufacturing and controls (CMC) reason for the refusal to file. ADVENTRX plans to meet with the FDA as soon as possible to discuss its response.

1 Mar 2010

Childhood obesity prevention: Prenatal and infancy period upto age 5 crucial

Efforts to prevent childhood obesity should begin far earlier than currently thought-perhaps even before birth-especially for minority children, according to a new study that tracked 1,826 women from pregnancy through their children's first five years of life.

1 Mar 2010

Short-term dose of losartan-M6PHSA reduces liver inflammation and fibrosis: Study

A recent study found that rats with advanced fibrosis that were administered a short-term dose of losartan-M6PHSA had reduced liver inflammation and fibrosis. Those animals treated with oral losartan alone did not experience a similar reduction in disease activity. Results of this study appear in the March issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

1 Mar 2010

Growth rate among non-radiologists who own/lease PET equipment is on the rise: Study

Just as with computed tomography (CT) and magnetic resonance imaging (MRI), the growth rate among non-radiologists who own or lease positron emission tomography (PET) equipment is also on the rise, contributing significantly to the ongoing issues surrounding self-referral and unnecessary utilization of imaging in the United States, according to a study published in the March issue of the Journal of the American College of Radiology (www.jacr.org)

1 Mar 2010

NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today its support for the second annual U.S. Rare Disease Day observance on February 28.

1 Mar 2010

Study shows ghrelin prevents acute liver damage, reduces oxidative stress and inflammation

Spanish researchers determined that rats treated with recombinant ghrelin displayed a reduction in liver fibrosis. Ghrelin, a stomach hormone, reduced the amount of fibrogenic cells by 25% in the treated rodents. Research further showed ghrelin prevented acute liver damage and reduced oxidative stress and inflammation in the animal models.

1 Mar 2010

Discovery of link between CTCF and other proteins may help understand disease mechanisms better

Scientists at the University of Essex have a greater understanding of how our genes are controlled following a major research project.

1 Mar 2010

Screening crucial for Triple A and more awareness needed

On Feb. 22, the day after America watched some of its strongest hearts compete in Vancouver on the 30th anniversary of the “Miracle on Ice” hockey game, a lucky patient at El Camino Hospital was recuperating from his own miracle.

1 Mar 2010

Researchers find gene regulator that plays key role in DS-AMKL

Between 5 and 10 percent of babies with Down syndrome develop a transient form of leukemia that usually resolves on its own. However, for reasons that haven't been clear, 20 to 30 percent of these babies progress to a more serious leukemia known as Down syndrome acute megakaryoblastic leukemia (DS-AMKL), which affects the blood progenitor cells that form red blood cells and platelets.

1 Mar 2010

BDSI provides update on product portfolio, key upcoming milestones

BioDelivery Sciences International, Inc. today provided a summary of its business overview webcast that was conducted on Thursday, February 25, 2010. Dr. Mark A. Sirgo, President and Chief Executive Officer, and Dr. Andrew L. Finn, Executive Vice President of Product Development, provided an update on the product portfolio, including development plans, anticipated timelines, and key upcoming milestones.

28 Feb 2010

Cancer News and Research

Latest Cancer News and Research

Study compares advertising tactics between indoor tanning and tobacco industries to market unhealthy products

SUVmax in head and neck squamous cell carcinoma patients predict overall survival

Determining personal risk for genetic disorders essential

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

Researchers figure out how ATP molecule broken down in cells

Study evaluates possible diet associations with ovarian cancer survival

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

New method using SGR to calculate rate of tumour growth developed

Breastfeeding and better hygiene may protect against peptic ulcer bacterium infection

Aprepitant drug can reduce nausea and vomiting when combined with other anti-nausea drugs

ADVENTRX' ANX-530 NDA: FDA issues refuse to file letter

Childhood obesity prevention: Prenatal and infancy period upto age 5 crucial

Short-term dose of losartan-M6PHSA reduces liver inflammation and fibrosis: Study

Growth rate among non-radiologists who own/lease PET equipment is on the rise: Study

NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance

Study shows ghrelin prevents acute liver damage, reduces oxidative stress and inflammation

Discovery of link between CTCF and other proteins may help understand disease mechanisms better

Screening crucial for Triple A and more awareness needed

Researchers find gene regulator that plays key role in DS-AMKL

BDSI provides update on product portfolio, key upcoming milestones

Cancer Research - Second Edition eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in